Clinical Trials Logo

Hemorrhage clinical trials

View clinical trials related to Hemorrhage.

Filter by:

NCT ID: NCT02360800 Completed - Hemorrhage Clinical Trials

Trial Comparing Tisseel as an Adjunct to Traditional Hemostasis After Redo Cardiac Surgery

RETICO
Start date: February 2, 2017
Phase: N/A
Study type: Interventional

Bleeding after redo cardiac surgery is a common, unresolved and consequences-heavy event as per present day. Tisseel (Baxter inc) sprayed on the already hemostased mediastinum jut before closing seems a promising technique to radically diminish bleeding. This study aims to verify this efficacy volume in chest drains) and possibly the consensual blood transfusion lessening.

NCT ID: NCT02356068 Completed - Hemorrhage Clinical Trials

Predictions of Bleeding During Liver Transplantation With Thromboelastometry

Start date: January 2015
Phase:
Study type: Observational [Patient Registry]

Patients with cirrhosis present complex coagulation defects. Conventional coagulation tests (INR, platelets count) can not predict bleeding or blood product requirements during liver transplantation. Thromboelastometry (TEM)analyser measures the viscoelastic of the whole blood coagulation generation and lysis. TEM results are available more rapidly than conventional tests and give additional information regarding coagulation strengh, platelet function, and fibrinolysis.

NCT ID: NCT02353585 Completed - Ischemic Stroke Clinical Trials

Novel Oral Anticoagulants in Stroke Patients

NOACISP
Start date: December 2014
Phase:
Study type: Observational [Patient Registry]

The present study will monitor and explore acute neurovascular emergencies in patients treated with NOACs compared to those under treatment with VKAs. The primary aims of this study are: (1) To investigate characteristics, management and outcome of intracranial hemorrhage (ICH) in patients treated with NOAC compared to VKA. (2) To investigate the management and outcome of patients with acute ischaemic stroke under NOAC compared to VKA.

NCT ID: NCT02353247 Completed - Clinical trials for Etonogestrel Contraceptive Implant, Bothersome Bleeding

Use of Norethindrone Acetate for Management of Bleeding Associated With the Etonogestrel Contraceptive Implant

Start date: August 2015
Phase: N/A
Study type: Interventional

The overall objective of this study is to confirm that oral progesterone is an effective way to manage bothersome bleeding; thus increasing the rate of continuation of the etonogestrel contraceptive implant in adolescents.

NCT ID: NCT02350335 Completed - Clinical trials for Aneurysmal Subarachnoid Hemorrhage

Transdermal Nicotine Replacement in Smokers With Acute Aneurysmal Subarachnoid Hemorrhage

NRT-SAH
Start date: January 2011
Phase: N/A
Study type: Interventional

All patients with acute aneurysmal hemorrhage are treated in accordance with our institutional protocol. After securing of the aneurysm, some smokers with acute aneurysmal hemorrhage are randomly assigned to transdermal nicotine replacement (NRT). The short- and long-term effect of NRT will be studied comparing non-smokers, smokers without NRT and smokers with NRT.

NCT ID: NCT02349490 Completed - Clinical trials for Gastrointestinal Hemorrhage

Seraseal for Endoscopic Hemostasis

Start date: November 2011
Phase: Phase 4
Study type: Interventional

Patients with active gastrointestinal bleeding can be included. 5ml of SerasealTM/Fastact (Wortham Laboratories, Chattanooga, USA), a CE-certified medical product for in human intraoperative use as hemostatic agent, is topically applied via catheters to the bleeding site. In group A, Seraseal is applied as initial method for hemostasis. In group B, Seraseal is applied after an initial failure of the institutional standard method. Homeostatic success is determined by 5 min without bleeding at gastrointestinal site. after application of Seraseal.

NCT ID: NCT02344069 Completed - Trauma Clinical Trials

Pilot Randomized Trial of Fibrinogen in Trauma Haemorrhage

Start date: February 2015
Phase: Phase 2
Study type: Interventional

Effect of immediate, pre-emptive fibrinogen concentrate in patients with trauma haemorrhage needing haemostatic resuscitation - a randomized, controlled, double-blinded investigator-initiated pilot trial

NCT ID: NCT02335580 Completed - Liver Cirrhosis Clinical Trials

Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis

Start date: December 2014
Phase:
Study type: Observational

The prevalence of portal vein thrombosis (PVT) in patients with liver cirrhosis is 5-20%. Current evidence regarding the effect of portal vein thrombosis on the prognosis of cirrhotic patients remains under debate. Considering that PVT potentially elevates the portal pressure and thereby increase the risk of variceal bleeding, we focus on the patients with high-risk varices and variceal bleeding as the study population. Thus, the main goals are to analyze the effect of PVT on the incidence of first variceal bleeding in patients without any prior bleeding history but with high-risk varices, the incidence of recurrent variceal bleeding in patients with a history of variceal bleeding, and the treatment failure rate of variceal bleeding in patients with acute variceal bleeding. Certainly, the survival is also observed in all patients.

NCT ID: NCT02335567 Completed - Clinical trials for Carotid Plaque Hemorrhage Appearance

Use of in Vivo 3T MR to Characterize Carotid Plaque in Patients and Correlate MR Findings With Symptoms

3TMR
Start date: June 2012
Phase: N/A
Study type: Observational

To compare two competing newly designed 3D sequences for black blood carotid plaque imaging techniques with the industry standard 2D sequnce for black blood.

NCT ID: NCT02334657 Completed - Clinical trials for Subarachnoid Hemorrhage

Prospective Study of Long-term Outcome After Non-aneurysmal Subarachnoid Hemorrhage

Start date: November 2013
Phase: N/A
Study type: Observational [Patient Registry]

Spontaneous subarachnoid hemorrhage (SAH) is usually caused by rupture of an intracranial aneurysm, but in up to 15% of patients with spontaneous SAH, no discernible bleeding source can be identified despite of repetitive radiological imaging. Patients, at least 18 months after ictus of a non-aneurysmal SAH, received a regular mail including a letter explaining the study purpose and the postal questionnaire consisting a short-form health survey with 36 simple questions. If we didn't receive answers after three months we made telephone interviews with the patients' family members or their general practitioner.